Development of SARS‐CoV‐2 animal vaccines using a stable and efficient NDV expression system

SARS CoV-2, a coronavirus, infects humans and animals. Animal species that are vulnerable would probably end up serving as mixing vessels. An alternative to preventing animals from acting as mixing vessels for the SARS CoV-2 is to vaccinate them. In this study, recombinant ND viruses expressing SARS CoV-2's spike or subunit protein were employed. The immunologic reactivity of rNDV was confirmed using Western blotting, neutralization, and other immunological techniques. The surface of the rNDV-vectored virus has SARS-CoV2 structural protein-1 (S-1) and the spike (S) protein inserted. In contrast to rNDV-S1, which induced a broad spectrum of T-cell responses but few antibodies, rNDV-S induced robust antibodies and an S-specific T-cell response after intramuscular vaccination. An rNDV-vectored vaccine candidate that is stable and effective and has strong humoral and cellular protection has been established.

(MMR)